Severe Pediatric Blunt Trauma—Successful ROTEM-Guided Hemostatic Therapy With Fibrinogen Concentrate and No Administration of Fresh Frozen Plasma or Platelets

2012 ◽  
Vol 19 (4) ◽  
pp. 453-459 ◽  
Author(s):  
Bernhard Ziegler ◽  
Christa Schimke ◽  
Peter Marchet ◽  
Birgit Stögermüller ◽  
Herbert Schöchl ◽  
...  
Keyword(s):  
Blunt Trauma ◽  
Fresh Frozen Plasma ◽  
Fibrinogen Concentrate ◽  
Fresh Frozen ◽  
Hemostatic Therapy ◽  
Frozen Plasma

EPTACOG ALFA. APPLICATION EXPERIENCE

2017 ◽  
Author(s):  
И. Нехаев ◽  
А. Приходченко ◽  
С. Ломидзе ◽  
А. Сытов
Keyword(s):  
Intensive Care Unit ◽  
Malignant Tumors ◽  
Coagulation Factors ◽  
Fresh Frozen Plasma ◽  
Massive Bleeding ◽  
Threshold Concentration ◽  
Damage Area ◽  
Fresh Frozen ◽  
Hemostatic Therapy ◽  
Frozen Plasma

Введение. Несмотря на переливания свежезамороженной плазмы и тромбоцитов, часто не удается достигнуть нужной «пороговой» концентрации факторов свертывания при массивных кровотечениях. При введении рекомбинантного активированного VII фактора (rFVIIa, эптаког альфа) этот процесс может быть ускорен, происходит «тромбиновый взрыв», который обеспечивает образование стабильной фибриновой пробки. Цель исследования: оценка эффективности и безопасности применения rVIIа в онкохирургии при коагулопатических кровотечениях. Материалы и методы. Обследовано 38 пациентов, оперированных по поводу злокачественных новообразований различной локализации, находившихся на лечении в отделении реанимации и интенсивной терапии № 1 в течение 2014 года. Результаты. Клиническая эффективность rFVIIа составила 94,7% при неэффективности стандартной гемостатической терапии и исчерпанных возможностях хирургического гемостаза при коагулопатических кровотечениях у онкохирургических больных. Заключение. rFVIIа обладает селективным действием (действует в зоне повреждения), что подтверждают данные коагулограммы и тромбоэлаcтометрии. rFVIIа не утяжеляет состояния больных. Introduction. Despite the transfusion of fresh frozen plasma and platelets it is often not possible to achieve the desired «threshold» concentration of coagulation factors in case of acute massive bleeding. Administration of recombinant activated VII factor (rFVIIa, eptacog alfa) can accelerates this process; «thrombin burst» occurs that provides the formation of a stable fi brin plug. Aim: to assess the effectiveness and safety of rVIIa usage in oncosurgery at coagulopathic bleedings. Materials and methods. In intensive care unit during 2014 we examined 38 patients with malignant tumors of various locations after surgery. Results. Clinical efficacy of rFVIIa was 94,7% with ineffectiveness of standard hemostatic therapy and exhausted possibilities of surgical hemostasis with coagulopathic bleedings in oncosurgical patients. Conclusion. rFVIIa has a targeted action (acts in damage area); coagulogram and thromboelometry data prove its action. rFVII does not make patients worse.

Perioperative management of coagulation

2006 ◽  
Vol 26 (S 02) ◽  
pp. S3-S14 ◽  
Author(s):  
P. Innerhofer
Keyword(s):  
Coagulation Factor ◽  
Fresh Frozen Plasma ◽  
Laboratory Evaluation ◽  
Blood Component ◽  
Actual Case ◽  
Fresh Frozen ◽  
Coagulation Factor Concentrates ◽  
Hemostatic Therapy ◽  
Frozen Plasma

SummaryGuidelines of official societies for diagnosis and therapy of intraoperatively occurring hypocoagulability rely mainly on data of patients receiving whole blood transfusions. They recommend -provided that laboratory evaluation shows deficiency (values >1.5 fold normal)- administration of fresh frozen plasma, cryoprecipitate and platelet concentrates (platelet count <50 000 or <100 000/μl). This article describes the pathogenesis of coagulopathy in the light of the special intraoperative setting, emphasizes recent changes of blood component preparation, transfusion triggers, effects of volume therapy and challenges standard laboratory assays as reliable guide for intraoperative hemostatic therapy. The role of thrombelastographic monitoring is discussed as well as an alternative strategy to compensate deficiencies by the use of coagulation factor concentrates instead of or in addition to transfusion of FFP, a new concept which is illustrated by the presentation of an actual case report.

Fibrinogen concentrate and cryoprecipitate but not fresh frozen plasma correct low fibrinogen concentrations following in vitro haemodilution

2013 ◽  
Vol 131 (5) ◽  
pp. e210-e213 ◽  
Author(s):  
Christian Fenger-Eriksen ◽  
Kirsten Christiansen ◽  
John Laurie ◽  
Benny Sørensen ◽  
Catherine Rea
Keyword(s):  
Fresh Frozen Plasma ◽  
Fibrinogen Concentrate ◽  
Fresh Frozen ◽  
Frozen Plasma

The In Vitro Effects of Fibrinogen Concentrate, Factor XIII and Fresh Frozen Plasma on Impaired Clot Formation After 60% Dilution

2008 ◽  
Vol 106 (5) ◽  
pp. 1360-1365 ◽  
Author(s):  
Thorsten Haas ◽  
Dietmar Fries ◽  
Corinna Velik-Salchner ◽  
Christian Reif ◽  
Anton Klingler ◽  
...  
Keyword(s):  
Factor Xiii ◽  
Fresh Frozen Plasma ◽  
Clot Formation ◽  
Fibrinogen Concentrate ◽  
Fresh Frozen ◽  
In Vitro Effects ◽  
Frozen Plasma

scholarly journals Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review

Critical Care ◽  
2011 ◽  
Vol 15 (5) ◽  
pp. R239 ◽  
Author(s):  
Sibylle Kozek-Langenecker ◽  
Benny Sørensen ◽  
John R Hess ◽  
Donat R Spahn
Keyword(s):  
Systematic Review ◽  
Clinical Effectiveness ◽  
Fresh Frozen Plasma ◽  
Fibrinogen Concentrate ◽  
Fresh Frozen ◽  
Frozen Plasma

scholarly journals A Still Rare Case of Congenital Afibrinogenemia

2018 ◽  
Vol 3 (2) ◽  
Keyword(s):  
Rare Case ◽  
Autosomal Recessive ◽  
Rare Condition ◽  
Preventive Treatment ◽  
Fresh Frozen Plasma ◽  
Autosomal Recessive Mode ◽  
Fibrinogen Concentrate ◽  
Fresh Frozen ◽  
Congenital Afibrinogenemia ◽  
Frozen Plasma

Congenital afibrinogenemia is characterized by the decrease or the absence of fibrinogen synthesis. It is a rare pathology that is transmitted autosomal recessive mode, with variable clinical demonstrations. The biological diagnosis consists in the presence of traces or absence of fibrogen with blood incoagulability. The coverage of this disease bases itself on the preventive treatment and replacement therapy based on fresh frozen plasma or fibrinogen concentrate. Through this case, we recall the various aspects of these rare condition clinical, biological, genetical as well as therapeutic plans.

scholarly journals Can Early Aggressive Administration of Fresh Frozen Plasma Improve Outcomes in Patients with Severe Blunt Trauma?—a Report by the Japanese Association for the Surgery of Trauma

Shock ◽  
2016 ◽  
Vol 45 (5) ◽  
pp. 495-501 ◽  
Author(s):  
Akiyoshi Hagiwara ◽  
Shigeki Kushimoto ◽  
Hiroshi Kato ◽  
Junichi Sasaki ◽  
Hiroshi Ogura ◽  
...  
Keyword(s):  
Blunt Trauma ◽  
Fresh Frozen Plasma ◽  
Japanese Association ◽  
Fresh Frozen ◽  
Frozen Plasma
Sign in / Sign up

Export Citation Format

Share Document